Kim Chi, MD, FRCPC, discusses the rationale and design of the phase 3 KLK2-comPAS trial evaluating pasritamig alone and in combination with JNJ-9401 in patients with mCRPC.
Commentary|Videos|July 7, 2026
Updated AUA/SUO Advanced Prostate Cancer guideline emphasizes role of PSMA-PET
Author(s)Kristen R. Scarpato, MD, MPH
Fact checked by: Hannah Clarke, Tracy Ann Politowicz
Kristen Scarpato, MD, discusses 2026 AUA/SUO Advanced Prostate Cancer Guideline amendment recommendations on the use of PSMA-PET imaging for staging and treatment selection.
Advertisement
Advertisement
In this interview, Kristen R. Scarpato, MD, MPH, discusses 2026 American Urological Association (AUA)/Society of Urologic Oncology (SUO) Advanced Prostate Cancer Guideline amendment recommendations regarding the role of prostate-specific membrane antigen (PSMA)-PET imaging across the prostate cancer continuum, highlighting its impact on disease detection, treatment decision-making, and ongoing questions surrounding its clinical implications.1 Scarpato is an associate professor of urology at Vanderbilt University Medical Center in Nashville, Tennessee.
Related to this article
Jeffrey M. Spier, MD, reviews evidence on ARPI dose reduction in prostate cancer and discusses monitoring treatment response, tolerability, and dose reescalation.
Jeffrey M. Spier, MD, discusses managing ARPI-related fatigue through dose adjustments, patient monitoring, and strategies to maintain treatment adherence.
Jack R. Andrews, MD, discusses BED-PSMA-411 findings comparing PSMA-PET detection rates and urinary excretion in prostate cancer biochemical recurrence.
Abraham Morgentaler, MD, reviews evidence showing no association between testosterone therapy and prostate cancer risk and explains the saturation model of androgen action.
The phase 1/2 CELC-G-201 study found preliminary antitumor activity and manageable toxicity with gedatolisib plus darolutamide in metastatic castration-resistant prostate cancer.
Longer-term findings from the phase 2 ARACOG study suggest differences in objectively measured cognitive function between ARPIs.
Engy Habashy, MD, discusses key takeaways from the 2025 AUA GSM guideline, including the role of androgens and hormonal therapies in managing genitourinary syndrome of menopause.
Advertisement
Advertisement